

Community-associated and healthcare-associated methicillin-resistant *Staphylococcus aureus* ~~(CA-MRSA)~~ in children: a microbiological and epidemiological study

Abstract

Novel methicillin-resistant *Staphylococcus aureus* have been causing infections in the community and are now invading hospitals. In this study we aimed to determine, using risk factors for healthcare associated infections as an epidemiological parameter, and antimicrobial susceptibility profile as a surrogate for SCCmec type and microbiological parameter, the characteristics of circulating *S. aureus* clinical isolates. From July 2009 to April 2012, *S. aureus* isolates from children hospitalized in Santa Casa de São Paulo, a tertiary care-center in São Paulo, Brazil, were included. . All isolates grew in cultures from sterile sites and we included only one isolate per patient. Fifty-five isolates were included during the study period, 47 from blood, six from abscesses, one from pleural fluid and one from spinal fluid. Regarding oxacillin resistance, 34 were methicillin susceptible *S. aureus*(MSSA) and 21 were methicillin-resistant *S. aureus*(MRSA). Eleven patients were excluded (5 MSSA and 6 MRSA) because clinical charts were not available for review, reducing the total to 29 MSSA and 15 MRSA isolates. After searching for risk factor for healthcare-associated infections, 11 of the 15 MRSA isolates were epidemiologically considered healthcare-associated MRSA(HCA-MRSA) and 4 community-associated MRSA (CA-MRSA). Using the microbiological classification (multiresistance), five were considered HCA-MRSA and 10 were considered CA-MRSA. Interestingly, of the 11 isolates considered epidemiological HCA-MRSA (presence of any risk factor), six had a microbiological profile (non-multiresistant) consistent with CA-MRSA circulating clones. Of the 11 isolates considered epidemiological HCA-MRSA, six had a microbiological profile consistent with CA-MRSA circulating clones. Our results clearly show that the boundaries between CA-MRSA and HCA- are increasingly difficult to determine.

Formatted: Font: Italic

Keywords

Staphylococcus aureus; MRSA; antimicrobial resistance; oxacillin

Introduction

Staphylococcus aureus commonly colonizes our species in different anatomical sites. Traditionally it is more frequently found in the nose. However, recent evidence suggests that oropharynx could be an even more important site of colonization¹. Some specific populations,

as cystic fibrosis patients, are more commonly colonized than the general population². Depending on host and pathogen factors, *S. aureus* may cause infection. Infectious syndromes include, but are not limited to respiratory, skin and soft tissue, osteoarticular and bloodstream infections. *S. aureus* is an important etiologic agent of both community- and healthcare-associated infections¹⁻³.

Resistance to antimicrobial agents has complicated the treatment of *S. aureus* infections. After penicillin resistance, methicillin resistance disseminated worldwide, first in the hospitals and eventually in the community³⁻⁶. These new community-associated methicillin resistant *S. aureus* (CA-MRSA) clones, described originally in the 1990s, have some differences when compared to the traditional healthcare-associated (HCA-MRSA) clones. CA-MRSA are usually resistant to less antimicrobial agents, usually only to beta-lactams and macrolides [\(and increasingly to clindamycin\)](#)³⁻⁵. These are the phenotypical implications of the presence of different Staphylococcal cassette chromosome *mec* (SCC*mec*) types. SCC*mec* is a mobile genetic element that includes *mecA* gene, responsible for methicillin resistance in *S. aureus*. CA-MRSA most commonly carry SCC*mec* types IV or V⁴⁻⁶. Some of these clones also have a specific virulence profile, frequently producing Panton-Valentine leukocidin and other typical virulence factors⁴⁻⁷.

These new clones have also been reported causing nosocomial infections, substituting, at least in part, traditional health-care associated MRSA clones. In [Brazil](#), although CA-MRSA is still not common, clones carrying SCC*mec* IV have been increasingly found in different hospitals⁸⁻¹². [Resistance to oxacillin in hospitals is common, varying from 30-60%](#)⁹⁻¹². In the present study, we aimed to characterize *S. aureus* clinical isolates regarding their epidemiological (presence or absence of risk factors for health-care associated infections) and microbiological (antimicrobial multiresistance or non-multiresistance as a surrogate for SCC*mec* type) profiles.

Methods

From July 2009 to April 2012, *S. aureus* isolates from children hospitalized in Santa Casa de São Paulo, a tertiary care-center in São Paulo, Brazil, were included. All isolates grew in cultures from sterile sites and we included only one isolate per patient. Bacterial identification was conducted using traditional biochemical methods (Gram stain, catalase, coagulase and DNase) and antimicrobial susceptibility testing was performed according to current Clinical and Laboratory Standards Institute criteria¹³.

Methicillin-resistant isolates resistant to four or more different classes of antibiotics were considered multiresistant (HCA-MRSA by microbiological classification), whereas isolates resistant to three or less classes were considered non-multiresistant (CA-MRSA by microbiological classification).

Clinical charts were read and searched for the presence or any risk factors for health-care associated infections, including hospitalization within the previous year, chronic disease that implicates in frequent contact (≥ 6 /year) with hospital environment, or current hospitalization

for at least 48 hours. Isolates were considered HCA-MRSA (epidemiologically) if any of these risk factors were present, and were considered CA-MRSA (epidemiologically) if they were all absent. The study was approved by the institutional ethics committee.

Results and Discussion

Fifty-five isolates were included during the study period, 47 from blood, six from abscesses, one from pleural fluid and one from spinal fluid. Regarding oxacillin resistance, 34 were MSSA and 21 were MRSA. Eleven patients were excluded (5 MSSA and 6 MRSA) because clinical charts were not available for review, reducing the total to 29 MSSA and 15 MRSA isolates.

After searching for risk factor for healthcare-associated infections, 11 of the 15 MRSA isolates were epidemiologically considered HCA-MRSA and 4 CA-MRSA. Using the microbiological classification (multiresistance), five were considered HCA-MRSA and 10 were considered CA-MRSA. Interestingly, of the 11 isolates considered epidemiological HCA-MRSA (presence of any risk factor), six had a microbiological profile (non-multiresistant) consistent with CA-MRSA circulating clones.

Although these novel SCCmec type IV MRSA clones were first reported in the community, there is increasing evidence that they are replacing traditional hospital circulating clones⁸⁻¹⁰. In Brazil, the Brazilian clone (SCCmec type III) have been disseminated nationally in hospitals, but recent evidence shows that different clones carrying a type IV cassette are disseminating as a cause of healthcare-associated infections^{11,12}.

Although the number of isolates included in our study is low, and we have not performed molecular typing, phenotypic susceptibility testing served as a surrogate for the SCCmec type, since we have previously and consistently reported the strong correlation between these parameters^{11,12}. In addition, its results clearly show that the boundaries between CA-MRSA and HCA- are increasingly difficult to determine. Nosocomial isolates cause infection in patients without risk factors and community isolates invade the hospital causing health-care associated infections. In these challenging epidemiological and microbiological situation, knowledge of local and global circulating clones is paramount to ensure the appropriate preventive and therapeutic approaches.

References

1. Bádúe Pereira MF, Mimica MJ, Carvalho RLB, Scheffer DK, Berezin EN. High rate of *Staphylococcus aureus* oropharyngeal colonization in children. J Infect. 2012;64:338-40.
2. Mimica MJ, Carvalho RL, Berezin EN, Damaceno N, Caiaffa-Filho HH. Comparison of five methods for oxacillin susceptibility testing of *Staphylococcus aureus* isolates from cystic fibrosis patients. Rev Inst Med Trop Sao Paulo. 2012;54:305-6.
3. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant *Staphylococcus aureus* (MRSA). Proc Natl Acad Sci U S A. 2002;99:7687-92.

Formatted: Portuguese (Brazil)

Formatted: Portuguese (Brazil)

4. Weber JT. Community-associated methicillin-resistant *Staphylococcus aureus*. Clin Infect Dis. 2005;41:S269-72.
5. Hultén KG, Kaplan SL, Gonzalez BE, Hammerman WA, Lamberth LB, Versalovic J, et al. Three-year surveillance of community-acquired *Staphylococcus aureus* infections in children. Pediatr Infect Dis J. 2006 Apr;25(4):349-53.
6. Qiao Y, Dong F, Song W, Wang L, Yang Y, Shen X. Hospital- and community-associated methicillin-resistant *Staphylococcus aureus*: a 6-year surveillance study of invasive infections in Chinese children. Acta Paediatr. 2013;102:1081-6.
7. Mimica MJ. Panton-Valentine leukocidin-positive *Staphylococcus aureus* skin infections. Clin Infect Dis. 2012;54:1517-8
8. Gonzalez BE, Rueda AM, Shelburne SA 3rd, Musher DM, Hamill RJ, Hulten KG. Community-associated strains of methicillin-resistant *Staphylococcus aureus* as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol. 2006; 27:1051-6.
9. Trindade PA, Pacheco RL, Costa SF, Rossi F, Barone AA, Mamizuka EM, et al. Prevalence of SCCmec type IV in nosocomial bloodstream isolates of methicillin-resistant *Staphylococcus aureus*. J Clin Microbiol. 2005; 43:3435-7.
10. Vidal PM, Trindade PA, Garcia TO, Pacheco RL, Costa SF, Reinert C, et al. Differences between "classical" risk factors for infections caused by methicillin-resistant *Staphylococcus aureus* (MRSA) and risk factors for nosocomial bloodstream infections caused by multiple clones of the staphylococcal cassette chromosome *mec* type IV MRSA strain. Infect Control Hosp Epidemiol. 2009;30:139-45.
11. Mimica, M.J.; Berezin, E.N.; Carvalho, R.B. Healthcare associated PVL-negative methicillin-resistant *Staphylococcus aureus* with SCCmec type IV. Pediatr Infect Dis J. 2009;28:934.
12. Mimica MJ, Berezin EN, Damasceno N, Carvalho RB. SCCmec Type IV, PVL-Negative, Methicillin-Resistant *Staphylococcus aureus* in Cystic Fibrosis Patients from Brazil. Curr Microbiol. 2011;62:388-90.
13. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement, M100-S23. Wayne, PA, USA: Clinical and Laboratory Standards Institute. 2013.

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Italic

~~Table 1. Epidemiological and microbiological classification of MRSA isolates from children hospitalized at Santa Casa de São Paulo, Brazil, 2009-2012.~~

Classification		Epidemiological		
		CA	HCA	Total
Microbiological	CA	4	6	10
	HCA	0	5	5
	Total	4	11	15

156

157